Ultragenyx Pharmaceutical, Inc. (RARE)
14.30
-0.10
(-0.69%)
USD |
NASDAQ |
Sep 11, 16:00
14.30
0.00 (0.00%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Enterprise Value : 2.314B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 2.314B |
| September 10, 2026 | 2.324B |
| September 09, 2026 | 2.315B |
| September 08, 2026 | 2.371B |
| September 04, 2026 | 2.412B |
| September 03, 2026 | 2.368B |
| September 02, 2026 | 3.516B |
| September 01, 2026 | 3.445B |
| August 31, 2026 | 3.386B |
| August 28, 2026 | 3.425B |
| August 27, 2026 | 3.489B |
| August 26, 2026 | 3.507B |
| August 25, 2026 | 3.509B |
| August 24, 2026 | 3.436B |
| August 21, 2026 | 3.447B |
| August 20, 2026 | 3.397B |
| August 19, 2026 | 3.487B |
| August 18, 2026 | 3.414B |
| August 17, 2026 | 3.477B |
| August 14, 2026 | 3.512B |
| August 13, 2026 | 3.501B |
| August 12, 2026 | 3.548B |
| August 11, 2026 | 3.558B |
| August 10, 2026 | 3.542B |
| August 07, 2026 | 3.455B |
| Date | Value |
|---|---|
| August 06, 2026 | 3.446B |
| August 05, 2026 | 3.359B |
| August 04, 2026 | 3.445B |
| August 03, 2026 | 3.367B |
| July 31, 2026 | 3.357B |
| July 30, 2026 | 3.468B |
| July 29, 2026 | 3.366B |
| July 28, 2026 | 3.462B |
| July 27, 2026 | 3.551B |
| July 24, 2026 | 3.552B |
| July 23, 2026 | 3.564B |
| July 22, 2026 | 3.626B |
| July 21, 2026 | 3.721B |
| July 20, 2026 | 3.712B |
| July 17, 2026 | 3.786B |
| July 16, 2026 | 3.879B |
| July 15, 2026 | 4.025B |
| July 14, 2026 | 4.057B |
| July 13, 2026 | 4.174B |
| July 10, 2026 | 4.233B |
| July 09, 2026 | 4.310B |
| July 08, 2026 | 4.316B |
| July 07, 2026 | 4.434B |
| July 06, 2026 | 4.221B |
| July 02, 2026 | 4.198B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 518.65B |
| Biogen, Inc. | 39.14B |
| BioMarin Pharmaceutical, Inc. | 16.06B |
| Ionis Pharmaceuticals, Inc. | 9.114B |
| Regeneron Pharmaceuticals, Inc. | 75.51B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -92.00M |
| Revenue (Quarterly) | 214.00M |
| Total Expenses (Quarterly) | 306.00M |
| EPS Diluted (Quarterly) | -0.9028 |
| Gross Profit Margin (Quarterly) | 80.37% |
| Profit Margin (Quarterly) | -42.99% |
| Earnings Yield | -40.85% |
| Normalized Earnings Yield | -40.88 |